Cargando…

Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a

BACKGROUND: Myelin water imaging is a magnetic resonance imaging (MRI) technique that quantifies myelin damage and repair in multiple sclerosis (MS) via the myelin water fraction (MWF). OBJECTIVE: In this substudy of a phase 3 therapeutic trial, OPERA II, MWF was assessed in relapsing MS participan...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolind, Shannon, Abel, Shawna, Taylor, Carolyn, Tam, Roger, Laule, Cornelia, Li, David K.B., Garren, Hideki, Gaetano, Laura, Bernasconi, Corrado, Clayton, David, Vavasour, Irene, Traboulsee, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421448/
https://www.ncbi.nlm.nih.gov/pubmed/35878575
http://dx.doi.org/10.1016/j.nicl.2022.103109
_version_ 1784777596907552768
author Kolind, Shannon
Abel, Shawna
Taylor, Carolyn
Tam, Roger
Laule, Cornelia
Li, David K.B.
Garren, Hideki
Gaetano, Laura
Bernasconi, Corrado
Clayton, David
Vavasour, Irene
Traboulsee, Anthony
author_facet Kolind, Shannon
Abel, Shawna
Taylor, Carolyn
Tam, Roger
Laule, Cornelia
Li, David K.B.
Garren, Hideki
Gaetano, Laura
Bernasconi, Corrado
Clayton, David
Vavasour, Irene
Traboulsee, Anthony
author_sort Kolind, Shannon
collection PubMed
description BACKGROUND: Myelin water imaging is a magnetic resonance imaging (MRI) technique that quantifies myelin damage and repair in multiple sclerosis (MS) via the myelin water fraction (MWF). OBJECTIVE: In this substudy of a phase 3 therapeutic trial, OPERA II, MWF was assessed in relapsing MS participants assigned to interferon beta-1a (IFNb-1a) or ocrelizumab (OCR) during a two-year double-blind period (DBP) followed by a two-year open label extension (OLE) with ocrelizumab treatment. METHODS: MWF in normal appearing white matter (NAWM), including both whole brain NAWM and 5 white matter structures, and chronic lesions, was assessed in 29 OCR and 26 IFNb-1a treated participants at weeks 0, 24, 48 and 96 (DBP), and weeks 144 and 192 (OLE), and in white matter for 23 healthy control participants at weeks 0, 48 and 96. RESULTS: Linear mixed-effects models of data from baseline to week 96 showed a difference in the change in MWF over time favouring ocrelizumab in all NAWM regions. At week 192, lesion MWF was lower for participants originally randomised to IFNb-1a compared to those originally randomised to OCR. Controls showed no change in MWF over 96 weeks in any region. CONCLUSION: Ocrelizumab appears to protect against demyelination in MS NAWM and chronic lesions and may allow for a more permissive micro environment for remyelination to occur in focal and diffusely damaged tissue.
format Online
Article
Text
id pubmed-9421448
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-94214482022-08-30 Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a Kolind, Shannon Abel, Shawna Taylor, Carolyn Tam, Roger Laule, Cornelia Li, David K.B. Garren, Hideki Gaetano, Laura Bernasconi, Corrado Clayton, David Vavasour, Irene Traboulsee, Anthony Neuroimage Clin Articles from the Special Issue on "Mapping Multiple Sclerosis: new frontiers - old challenges" Edited by Hartwig Siebner, Vanessa Wiggermann, Martina Absinta, Mark Mühlau, Oh Jiwon and Maria A. Rocca BACKGROUND: Myelin water imaging is a magnetic resonance imaging (MRI) technique that quantifies myelin damage and repair in multiple sclerosis (MS) via the myelin water fraction (MWF). OBJECTIVE: In this substudy of a phase 3 therapeutic trial, OPERA II, MWF was assessed in relapsing MS participants assigned to interferon beta-1a (IFNb-1a) or ocrelizumab (OCR) during a two-year double-blind period (DBP) followed by a two-year open label extension (OLE) with ocrelizumab treatment. METHODS: MWF in normal appearing white matter (NAWM), including both whole brain NAWM and 5 white matter structures, and chronic lesions, was assessed in 29 OCR and 26 IFNb-1a treated participants at weeks 0, 24, 48 and 96 (DBP), and weeks 144 and 192 (OLE), and in white matter for 23 healthy control participants at weeks 0, 48 and 96. RESULTS: Linear mixed-effects models of data from baseline to week 96 showed a difference in the change in MWF over time favouring ocrelizumab in all NAWM regions. At week 192, lesion MWF was lower for participants originally randomised to IFNb-1a compared to those originally randomised to OCR. Controls showed no change in MWF over 96 weeks in any region. CONCLUSION: Ocrelizumab appears to protect against demyelination in MS NAWM and chronic lesions and may allow for a more permissive micro environment for remyelination to occur in focal and diffusely damaged tissue. Elsevier 2022-07-19 /pmc/articles/PMC9421448/ /pubmed/35878575 http://dx.doi.org/10.1016/j.nicl.2022.103109 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Articles from the Special Issue on "Mapping Multiple Sclerosis: new frontiers - old challenges" Edited by Hartwig Siebner, Vanessa Wiggermann, Martina Absinta, Mark Mühlau, Oh Jiwon and Maria A. Rocca
Kolind, Shannon
Abel, Shawna
Taylor, Carolyn
Tam, Roger
Laule, Cornelia
Li, David K.B.
Garren, Hideki
Gaetano, Laura
Bernasconi, Corrado
Clayton, David
Vavasour, Irene
Traboulsee, Anthony
Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a
title Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a
title_full Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a
title_fullStr Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a
title_full_unstemmed Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a
title_short Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a
title_sort myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a
topic Articles from the Special Issue on "Mapping Multiple Sclerosis: new frontiers - old challenges" Edited by Hartwig Siebner, Vanessa Wiggermann, Martina Absinta, Mark Mühlau, Oh Jiwon and Maria A. Rocca
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421448/
https://www.ncbi.nlm.nih.gov/pubmed/35878575
http://dx.doi.org/10.1016/j.nicl.2022.103109
work_keys_str_mv AT kolindshannon myelinwaterimaginginrelapsingmultiplesclerosistreatedwithocrelizumabandinterferonbeta1a
AT abelshawna myelinwaterimaginginrelapsingmultiplesclerosistreatedwithocrelizumabandinterferonbeta1a
AT taylorcarolyn myelinwaterimaginginrelapsingmultiplesclerosistreatedwithocrelizumabandinterferonbeta1a
AT tamroger myelinwaterimaginginrelapsingmultiplesclerosistreatedwithocrelizumabandinterferonbeta1a
AT laulecornelia myelinwaterimaginginrelapsingmultiplesclerosistreatedwithocrelizumabandinterferonbeta1a
AT lidavidkb myelinwaterimaginginrelapsingmultiplesclerosistreatedwithocrelizumabandinterferonbeta1a
AT garrenhideki myelinwaterimaginginrelapsingmultiplesclerosistreatedwithocrelizumabandinterferonbeta1a
AT gaetanolaura myelinwaterimaginginrelapsingmultiplesclerosistreatedwithocrelizumabandinterferonbeta1a
AT bernasconicorrado myelinwaterimaginginrelapsingmultiplesclerosistreatedwithocrelizumabandinterferonbeta1a
AT claytondavid myelinwaterimaginginrelapsingmultiplesclerosistreatedwithocrelizumabandinterferonbeta1a
AT vavasourirene myelinwaterimaginginrelapsingmultiplesclerosistreatedwithocrelizumabandinterferonbeta1a
AT traboulseeanthony myelinwaterimaginginrelapsingmultiplesclerosistreatedwithocrelizumabandinterferonbeta1a